Corporation, a biopharmaceutical company specializing in the discovery, development, and commercialization of proprietary ...

The company is expecting 2025 EPS to range from $15.25 to $16.25, below the $16.33 FactSet consensus. Revenue is expected to decline by a mid-single-digit percent on a constant currency basis, as ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company with a market capitalization of $3.06 billion, focuses on developing and commercializing innovative medicines to address unmet ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.

Sales teams are always looking for ways to improve efficiency, close deals faster, and keep leads engaged. A Sales CRM system plays a vital role in managing customer interactions, tracking leads, and ...

By expanding our product ... analysis is clear and in no way misleading or deceptive. To further protect the integrity of our editorial content, we keep a strict separation between our sales ...

Quarterly net income of $1,225 million Cash flows from operating activities of $1,789 million and cash flows from operating ...

Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%.